Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Aurelius Health Group vs Defy Medical

Aurelius Health Group
Graded #275

Higher grade

vs+2.0999999999999943
Defy Medical
Graded #326

Lower grade

The verdict

Aurelius Health Group takes it — 62.3/100 to 60.2/100.

Aurelius Health Group grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Aurelius Health Group is a telehealth platform built around compounded tirzepatide microdosing — a low-dose dual GIP/GLP-1 protocol rather than standard full-dose therapy — with optional NAD+, L-carnitine,…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueAurelius Health Group +15
60
45
Dose & formulationDefy Medical +4
52
56
Clinical oversightDefy Medical +4
76
80
Labs & monitoringDefy Medical +2
63
65
FulfillmentDefy Medical +2
61
63
Contract termsAurelius Health Group +6
61
55
Aurelius Health Group · left barDefy Medical · right bar

The numbers

MetricAurelius Health GroupDefy Medical
WeighScore62.3/10060.2/100
GradeCC
Scorecard rank#275#326
SemaglutideNot disclosedNot disclosed
Tirzepatide$199/mo (microdose tier, compounded)Not disclosed
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyYes
Aurelius Health Group

Graded #275 · C

Strengths

  • Pricing fully published and bundled: $89 first month, then $199/mo all-in — more transparent than most compounded brands
  • LegitScript Certified
  • Care-inclusive model: consults, monthly monitoring, and secure messaging rather than Rx-only
  • Unusually candid about the limited evidence base for microdosing

Where it loses points

  • Microdose-only model — sub-therapeutic doses have thinner trial evidence and likely smaller weight loss than full-dose tirzepatide
  • No semaglutide or standard full-dose option
  • No named compounding pharmacy partner
  • No state list and no named medical director or pharmacist-in-charge
Defy Medical

Graded #326 · C

Strengths

  • Multiple GLP-1 options: semaglutide, tirzepatide, liraglutide
  • Offers injection, ODT, and oral drop delivery forms
  • Comprehensive blood testing and named medical director
  • Established clinic with strong Trustpilot review volume

Where it loses points

  • GLP-1 pricing not published on the website
  • States served and shipping limits not disclosed
  • Compounded versus brand status not stated online
  • Lab-heavy, consult-first model may cost more upfront

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard